Articles By Jack Cush, MD
Inflammatory Arthritis and Hidradenitis Suppurativa
09 December 2022
Hidradenitis suppurativa (HS) (also called acne inversa), is a chronic inflammatory skin disorder affecting apocrine gland-bearing skin in the axillae, groin, and under the breasts and is characterised by persistent or recurrent
Read Article
Biosimilar Bonanza in 2023 (12.9.2022)
09 December 2022
Dr. Jack Cush reviews more than a dozen news and journal articles from this past week on RheumNow.com.
Read Article
Telemedicine Updates
08 December 2022
Several recent articles inform us of recent trends in Telemedicine.
Read Article
ACR Urges Congress to Prioritize Medicare Pay Cuts, Prior Authorization, and Telehealth
08 December 2022
As the legislative session comes to a close, the American College of Rheumatology (ACR) is calling on members of Congress to include the Improving Seniors’ Timely Access to Care Act (H.R. 3173/S. 3018), the Supporting Medicare Providers Act of 2022 (H.R.
Read Article
Bimekizumab Efficacy in TNF-Refractory Psoriatic Arthritis
07 December 2022
Bimekizumab, a selective inhibitor of interleukin (IL)-17F and IL-17, has shown superior efficacy and safety in a 16 week trial in patients with active psoriatic arthritis who previously failed therapy with tumour necrosis factor-α (TNFi) inhibitors.
Read Article
The Top 10 Research Priorities in Psoriatic Arthritis
06 December 2022
A survey of 317 carers and clinicians focused on psoriatic arthritis has set an agenda of the top 10 research questions for psoriatic arthritis (PsA).
Read Article
Multi-ancestry analysis reveals novel genetic loci associated with Osteoarthritis
06 December 2022
The first large multi-ancestry genetics study of osteoarthritis (OA) has found 10 novel OA-associated genetic loci, and results showed some of the OA-associated regions are robustly found in every population ancestry studied.
Read Article
TARGET Trial - Cardiovascular Risk Reduction in Rheumatoid Arthritis
05 December 2022
A recent randomised clinical trial suggests immunomodulators reduce arterial inflammation, and thereby cardiovascular (CV) risk, but shows no significant benefit to TNF inhibitors over triple therapy in patients with rheumatoid arthritis (RA).
Read Article
Comparing Biosimilar Growth in the US, Germany, and Switzerland
05 December 2022
The biosimilar landscape will change dramatically in 2023, following the successful rollouts in other countries in Europe.
Read Article
Lupus Linked With Greater Risk of Cardiovascular Complications of Childbirth
02 December 2022
Pregnant women with systemic lupus erythematosus (SLE) were more prone to cardiovascular complications during delivery, and their risk seems to have increased over the past 15 years, according to national administrative data.
Read Article